The APL test (Antiphospholipid Antibodies) is a blood test used to identify autoimmune antibodies that attack phospholipids or proteins associated with them (such as β2-glycoprotein I). These antibodies are mainly associated with Antiphospholipid Syndrome (APS), which is characterized by an increased risk of blood clotting (thrombosis) in venous or arterial vessels, recurrent miscarriages, and pregnancy complications such as preeclampsia. The APL test includes detection of three main markers: anticardiolipin antibodies (IgG/IgM), anti-β2-glycoprotein I antibodies (IgG/IgM), and lupus anticoagulant (using coagulation-based methods). The persistent presence of these antibodies in two tests at least 12 weeks apart, along with clinical symptoms, is essential for a definitive diagnosis of APS. These antibodies can sometimes be detected in other diseases like systemic lupus erythematosus (SLE) or infections, so interpretation of results should be made considering the clinical context and ruling out transient factors such as infections. Timely diagnosis of APL is crucial for preventing life-threatening complications and for therapeutic management, including anticoagulant use.
